A controlled study of WIN 27,147-2 in the treatment of depression

In two collaborating hospitals, 37 depressed male and female patients were treated for four weeks in a placebo-controlled double-blind study of WIN 27,147-2. The WIN 27,147-2 group showed a statistically significant reduction in the anxious-depression factor of the Brief Psychiatric Rating Scale and the somatization factor of the Hamilton Depression Scale, plus a greater incidence of drowsiness. The placebo group showed a relatively greater improvement on the retardation scale of the Nurses Observation Scale for Inpatient Evaluation plus a greater incidence of akathisia and restlessness. These findings suggest a drug with anti-depressant anxiolytic actions with sedative properties.